NORLIQVA

Generic: AMLODIPINE

Manufacturer: Cmp Pharma, Inc.

Calcium Channel Blocker [EPC]Dihydropyridine Calcium Channel Blocker [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Corticosteroid [EPC]Proton Pump Inhibitor [EPC]
257,794
Total Reports
98,683
Serious Reports
28,124
Death Reports
30
Reported Reactions
Death Report Ratio: High (10.91%)

Patient Demographics

Male
111,102
Female
125,186

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for NORLIQVA.

# Reaction Reports % of Total
1 FATIGUE 15,695
6.1%
2 DIARRHOEA 14,038
5.5%
3 NAUSEA 13,425
5.2%
4 DYSPNOEA 13,215
5.1%
5 DRUG INEFFECTIVE 12,076
4.7%
6 OFF LABEL USE 11,235
4.4%
7 DIZZINESS 10,672
4.2%
8 HEADACHE 9,888
3.8%
9 ACUTE KIDNEY INJURY 9,369
3.6%
10 PAIN 9,169
3.6%
11 VOMITING 8,736
3.4%
12 FALL 8,492
3.3%
13 ASTHENIA 8,485
3.3%
14 HYPOTENSION 8,369
3.3%
15 MALAISE 7,952
3.1%
16 DEATH 7,765
3.0%
17 HYPERTENSION 7,761
3.0%
18 ARTHRALGIA 7,651
3.0%
19 PNEUMONIA 7,474
2.9%
20 COUGH 6,406
2.5%
21 RASH 6,283
2.4%
22 BLOOD PRESSURE INCREASED 6,221
2.4%
23 PAIN IN EXTREMITY 6,206
2.4%
24 WEIGHT DECREASED 5,968
2.3%
25 TOXICITY TO VARIOUS AGENTS 5,927
2.3%
26 PRURITUS 5,889
2.3%
27 DRUG INTERACTION 5,844
2.3%
28 DECREASED APPETITE 5,773
2.2%
29 PYREXIA 5,721
2.2%
30 CHRONIC KIDNEY DISEASE 5,370
2.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.